# A Locally Injected Bradykinin Antagonist for TReatment of OSteoarthritiS

> **NCT01091116** · PHASE2 · COMPLETED · sponsor: **Menarini Group** · enrollment: 423 (actual)

## Conditions studied

- Osteoarthritis, Knee

## Interventions

- **DRUG:** MEN16132 - 0.125 mg
- **DRUG:** MEN16132 - 0.25 mg
- **DRUG:** MEN16132 - 0.5 mg
- **DRUG:** MEN16132 - 0.5 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01091116
- **Lead sponsor:** Menarini Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2011-02
- **Final completion:** 2011-03
- **Target enrollment:** 423 (ACTUAL)
- **Last updated:** 2013-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01091116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01091116, "A Locally Injected Bradykinin Antagonist for TReatment of OSteoarthritiS". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01091116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*